Table 4 Correlation of PARK-2 promoter methylation with clinical parameters among breast cancer patients
S No. | Variables | Total | Parkin Promoter | P valuea | OR (95%CI) | ||
|---|---|---|---|---|---|---|---|
Unmethylated | Methylated | ||||||
1 | Age (Years) | < 50 | 30 | 14 (47) | 16 (53) | 1.000 | 1.0259 (0.4617–2.2791) |
≥50 | 126 | 58 (46) | 68 (54) | ||||
2 | Weight (Kg) | < 60 | 75 | 36 (48) | 39 (52) | 0.748 | 1.1538 (0.6143–2.1672) |
≥60 | 81 | 36 (44) | 45 (56) | ||||
3 | Tumour size (cm) | < 4’ | 73 | 37 (51) | 36 (49) | 0.335 | 1.4095 (0.7487–2.6537) |
≥4 | 83 | 35 (42) | 48 (58) | ||||
4 | Clinical Stage | I + II | 88 | 36 (41) | 52 (59) | 0.148 | 0.6154 (0.3251–1.1650) |
III + IV | 68 | 36 (53) | 32 (47) | ||||
5 | Histological gradeb | WD | 54 | 33 (61) | 21 (39) | 0.007* | 2.5385 (1.2894–4.9974) |
MD + PD | 102 | 39 (38) | 63 (62) | ||||
6 | Lymph Node | Negative | 81 | 42 (52) | 39 (48) | 0.151 | 1.6154 (0.8559–3.0487) |
Positive | 75 | 30 (46) | 45 (54) | ||||
7 | Menopause | Pre | 38 | 23 (61) | 15 (39) | 0.061 | 2.1592 (1.0235–4.5549) |
Post | 118 | 49 (42) | 69 (58) | ||||
8 | ERc | Negative | 81 | 41 (51) | 40 (49) | 0.264 | 1.4548 (0.7723–2.7404) |
Positive | 75 | 31 (41) | 44 (59) | ||||
9 | PRd | Negative | 103 | 49 (48) | 54 (52) | 0.735 | 1.1836 (0.6076–2.3056) |
Positive | 53 | 23 (43) | 30 (57) | ||||
10 | Her-2e | Negative | 111 | 61 (55) | 50 (45) | 0.001* | 3.7709 (1.7351–8.1925) |
Positive | 45 | 11 (24) | 34 (76) | ||||
11 | TNBCf | No | 106 | 49 (46) | 57 (54) | 1.000 | 1.0092 (0.5140–1.9812) |
Yes | 50 | 23 (46) | 27 (54) | ||||